Researchers from the Yale University filed for protection of a multi-modal approach to predict the progression risk of a heart condition using artificial intelligence algorithms applied to cardiovascular videos.
Simcere Zaiming Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting zinc transporter ZIP6 (SLC39A6; LIV-1) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
Beijing Primegene Therapeutics Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of sepsis, stroke, atherosclerosis, gout, Alzheimer's disease, Parkinson’s disease, type I diabetes and cancer, among others.
Innovent Biologics (Suzhou) Co. Ltd. has described antibody-stimulating antibody conjugates (ISACs) comprising antibody targeting folate receptor α (FOLR1; FR-α) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently bound to toll-like receptor 7 (TLR7) and/or toll-like receptor 8 (TLR8) agonist through a linker reported to be useful for the treatment of cancer.
Sevenless Therapeutics Ltd. has patented son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, parkinsonism, neurofibromatosis type 1, atopic dermatitis and cholestasis, among others.
Indiana University Research and Technology Corp. has divulged peptides acting as dual agonists of amylin receptor and calcitonin (CALCR; CT-R) receptor and its conjugates with incretin reported to be useful for the treatment of obesity.
Humanwell Healthcare (Group) Co. Ltd. has described fused ring compounds acting as angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of disorders of the ovary and female reproductive tract, metabolic diseases, cardiovascular, eye, gastrointestinal, neurological, renal and respiratory disorders.
Yichang Humanwell Pharmaceutical Co. Ltd. has discovered nociceptin receptor (OPRL1; KOR3; ORL1) agonists reported to be useful for the treatment of pain.
Researchers from Iama Therapeutics Srl and the Italian Institute of Technology have prepared and tested solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of complex regional pain syndromes, Alzheimer’s disease, Down syndrome, glioma, Rett syndrome, temporal lobe epilepsy, traumatic brain injury and obsessive-compulsive disorder.
RSS
